---
figid: PMC11011201__tbae007f2
pmcid: PMC11011201
image_filename: tbae007f2.jpg
figure_link: /pmc/articles/PMC11011201/figure/f2/
number: Figure 2
figure_title: ''
caption: The historical value of markets for antibodies approved in 2023. These include
  anti-programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1
  (PD-L1) mAbs, mAbs with targets in the TH17 pathway, antibodies targeting multiple
  myeloma, anti-C5 (complement) mAbs, anti-CD20 antibodies (subdivided into market
  for targeting B-cells for cancer vs the market for targeting B-cells for autoimmune
  disorders), anti-respiratory syncytial virus (RSV) mAbs, biologics targeting FcRn,
  anti-amyloid-Î² mAbs (all on left side numbers) and the total value of antibody-based
  biologics worldwide (right side numbers). These data are derived from references
  (, , ).
article_title: Structure and function of therapeutic antibodies approved by the US
  FDA in 2023.
citation: William R Strohl. Antib Ther. 2024 Apr;7(2):132-156.
year: '2024'

doi: 10.1093/abt/tbae007
journal_title: Antibody Therapeutics
journal_nlm_ta: Antib Ther
publisher_name: Oxford University Press

keywords:
- therapeutic antibodies
- bispecific antibodies
- new molecular entities
- US FDA

---
